What's Happening?
Researchers at the Centre for Genomic Regulation (CRG), led by ICREA Research Professor Luciano Di Croce, PhD, have identified a six-gene scoring system, named PHFScore, that can reliably predict the survival of patients with acute myeloid leukemia (AML).
The study, published in Science Advances, involved a combination of laboratory experiments with mice and analysis of human patient records. The team initially focused on the PHF19 gene, known to suppress blood cancer formation. They discovered that the activity levels of six specific genes—CARMIL1, HOPX, ALDH1A1 (more active in poor outcomes) and CALR, STAR, PHF19 (less active in poor outcomes)—collectively provide accurate prognostic information. Cells lacking PHF19 exhibited stem-like features, reduced responsiveness to chemotherapy, and increased malignancy, indicating that the gene plays a crucial role in preventing leukemia cells from remaining in an immature, plastic state.
Why It's Important?
This discovery holds significant importance for U.S. healthcare and oncology, particularly in improving the prognosis and treatment of acute myeloid leukemia. AML is known for its variable outcomes, making accurate patient stratification crucial for effective treatment planning. The PHFScore offers a simpler and more cost-effective method for predicting patient survival compared to broader genetic profiling, as it only requires measuring the activity of six genes from a bone marrow sample. This could enable clinicians to identify high-risk patients earlier, allowing for more aggressive or tailored therapeutic interventions. Furthermore, the identification of specific genes, some previously unlinked to blood cancer, opens new avenues for therapeutic targets, potentially leading to the development of novel drugs that can overcome chemotherapy resistance and induce differentiation in leukemia cells.
What's Next?
The immediate next step involves further validation of the PHFScore in larger, diverse patient cohorts to confirm its predictive accuracy across different AML subtypes and populations. Researchers will also delve deeper into the functions of the newly identified genes (CARMIL1, HOPX, ALDH1A1, CALR, STAR) to understand their precise roles in leukemia progression and chemotherapy resistance. This could lead to the development of targeted therapies that modulate the activity of these genes. The findings also suggest the potential for integrating PHFScore into routine clinical practice as a prognostic tool, which would require regulatory approval and widespread adoption by medical institutions. Ultimately, this research aims to translate into improved clinical outcomes for AML patients through more personalized and effective treatment strategies.
Beyond the Headlines
The PHFScore not only offers a practical tool for AML prognosis but also sheds light on the fundamental biological mechanisms underlying cancer plasticity and drug resistance. The concept that cancer cells' ability to retain a 'stem-like' or immature state contributes to their malignancy and resistance to treatment has broader implications for understanding and combating other types of cancer. This research highlights the critical role of epigenetic regulators, like PHF19, in maintaining cellular differentiation and preventing cancerous transformation. The study also underscores the power of integrating basic science (mouse models) with clinical data (patient records) to uncover clinically relevant insights. This interdisciplinary approach is crucial for advancing cancer research and developing innovative therapies that target the core vulnerabilities of cancer cells, moving beyond symptomatic treatment to address the root causes of the disease.
